Our recent activity

Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Round

Considering the complex nature of pain, Medasense technology uses a unique multi- parametric sensor platform and advanced AI algorithms to convert complicated data into a patient’s “Signature of Pain”. The technology, which is currently utilized in operating rooms and critical care settings, where patients are under anaesthesia and unable to communicate, enables clinicians to personalize treatment: control pain, avoid overdose, and eliminate doubt. The company has also been active in the implementation of its technology on COVID-19 ventilated patients.

Studies have shown that NOL monitoring can potentially reduce hypotensive events and opioid consumption during surgery, and reduce postoperative pain experienced by patients. This addresses a widespread need. It is estimated that 50% of surgical patients suffer from moderate to severe postoperative pain and 12% suffer adverse events due to pain relief medication. These can result in extended hospitalization, additional healthcare costs, and a 50% increase in hospital readmissions.

Josep Ll. Sanfeliu, founding partner of Asabys Partners stated: “Medasense is a model startup, having successfully introduced a disruptive medical device technology to the market. Its artificial intelligence solution is impacting clinical outcomes to benefit patients and to enable better use of healthcare resources.”

“Together with our trusted investors, who share our passion to improve pain management, we expect to make a significant contribution to enhancing pain care. This funding round will allow us to expand and further consolidate commercial deployment of NOL technology in Europe through our distribution agreement with Medtronic and to complete the process of obtaining FDA approval for commercialization in the U.S.,” said Galit Zuckerman-Stark, Medasense founder and CEO.

About Medasense and NOL Technology

Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to personalize pain control and avoid overmedication. Medasense’s flagship product, the PMD-200TM with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of a proprietary non-invasive sensor platform and artificial intelligence.

The PMD-200 is used to optimize pain management in critical care and operating room settings, where patients are unable to communicate.

The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America, Israel and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid sparing, less postoperative pain experienced by patients in the post anaesthesia care unit, and reduced cost of care.

Watch Medasense’s 1-minute video

September 8, 2021

#EntrevistaBiospain2021 | Asabys, el primer inversor de salud español acreditado por su compromiso con los Objetivos de Desarrollo Sostenible

Hablamos con Clara Campàs y Josep Lluís Sanfeliu, fundadores del fondo de capital riesgo Asabys Partners, Silver Sponsor de Biospain 2021, sobre su compromiso con la sostenibilidad y el futuro…
July 8, 2021

Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies

READ THIS NEWS IN SPANISH Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases Joint development agreement represents a promising step towards a…
Asabys Partners and Bureau VeritasInternal
May 13, 2021

Asabys Partners certifies with Bureau Veritas its Social Responsibility Management System aligned with the Sustainable Development Goals (SDGs) from United Nations

Asabys Partners, venture capital firm investing in innovative companies within the healthcare space, announces today the certification of its management system of CSR aligned with the Sustainable Development Goals from…

Leave a Reply